MSCs are a class of multipotent cells found in human tissues, such as bone marrow, adipose tissue, dental pulp, and periosteum, a layer of connective tissue that envelops the bones. They are also known as: Mesenchymal Stem Cells, Medicinal Signaling Cells, Mesenchymal Stromal Cells, and Marrow Stromal Cells. [Read more…]
The LA Times released a compelling article highlighting the mounting evidence that stem cell treatments will be some of the highest priced treatments within the medical marketplace. Titled “Sky-high price of new stem cell therapies is a growing concern,” the author Michael Hiltzik explores the often exorbitant costs associated with stem cell procedures.
In a powerful statement that summarizes the author’s position, he writes, “The evidence is already mounting that stem cell and other advanced biologic treatments will be among the most expensive therapies in the medical arsenal.” As examples of expensive cell therapy procedures, Hiltzik cites that Prochymal, a mesenchymal stem cell treatment approved in Canada, can costs as much as $200K, while Provenge, a cell-based vaccine for prostate cancer, can cost nearly $100K to extend a patient’s life by a few months. [Read more…]
The history of cord blood banking is fascinating, because the service did not exist on a wide-spread basis until a few decades ago. Below, we introduce key historical events that have affected cord blood and cord tissue storage and how they could impact you, your family, or your investment portfolio.
To analyze the emerging global market for mesenchymal stem cells (MSCs), it is important to define the cell type. Broadly defined, mesenchymal stem cells are multi-potent stem cells that can differentiate into a diverse range of cell types. More specifically, mesenchymal stem cells are non-hematopoietic stromal cells that are capable of differentiating into, and assisting in the repair of, tissues of both intra-mesenchymal and extra-mesenchymal lineages.
The “Global Cord Blood Banking Industry Report” reveals key benchmarks to track and why you should care. Benchmarks are critical to assess, because the cord blood banking industry has matured substantially over the past few years, creating both serious threats and novel opportunities.
Therefore, judging individual company performance relative to the broader cord blood marketplace has become substantially more complex.